导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -10.29% | 3766/4773 |
| 近一周 | -2.17% | 3515/5465 |
| 近一月 | -1.28% | 1094/5421 |
| 近一季 | -0.48% | 1072/5231 |
| 近半年 | -8.61% | 3530/4920 |
| 近一年 | -8.37% | 3304/4394 |
| 近两年 | 26.19% | 2452/2954 |
| 近三年 | 11.02% | 1730/2253 |
| 成立以来 | -0.03% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-6.36% 4111/4961 |
-5.33% 3563/5312 |
- - |
- - |
| 2025 | 8.02% 2912/4813 |
-6.63% 3377/3635 |
3.33% 1046/4076 |
14.25% 2932/4524 |
-2.01% 3060/4813 |
| 2024 | 26.50% 223/3463 |
1.33% 887/2808 |
-2.63% 1217/3014 |
21.93% 527/3129 |
5.16% 629/3463 |
| 2023 | -5.50% 745/2656 |
3.58% 1165/2280 |
-1.27% 466/2385 |
0.79% 341/2515 |
-8.32% 2278/2655 |
| 2022 | -12.45% 284/2207 |
-7.85% 255/1919 |
1.52% 1463/2016 |
-10.14% 352/2113 |
4.15% 580/2208 |
| 2021 | -3.14% 889/1822 |
-2.58% 670/1255 |
-1.47% 1168/1330 |
-0.29% 485/1466 |
1.20% 986/1822 |
| 2020 | -0.95% 948/1250 |
-15.22% 978/1028 |
6.07% 871/1067 |
5.74% 896/1164 |
4.17% 859/1184 |
| 2019 | 20.29% 667/1092 |
22.20% 577/739 |
0.29% 171/788 |
-4.01% 755/850 |
2.25% 869/918 |
| 2018 | -19.84% 181/834 |
- - |
-7.84% 187/631 |
-0.24% 175/660 |
-9.15% 132/682 |
| 2017 | 1.28% 453/714 |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 汇添富中证上海国企ETF联接A VS. 长安沪深300非周期A(740101) |